Smoothened Agonist (SAG) HCl

For research use only. Not for use in humans.

目录号:S7779

Smoothened Agonist (SAG) HCl Chemical Structure

CAS No. 2095432-58-7

Smoothened Agonist (SAG) HCl是一种细胞渗透性Smoothened (Smo)激动剂,其在Shh-LIGHT2细胞中的EC50约为3 nM。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 3660.93 现货
RMB 954.43 现货
RMB 2024.65 现货
RMB 6110.42 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Smoothened Agonist (SAG) HCl发表文献34篇:

产品安全说明书

Hedgehog/Smoothened抑制剂选择性比较

生物活性

产品描述 Smoothened Agonist (SAG) HCl是一种细胞渗透性Smoothened (Smo)激动剂,其在Shh-LIGHT2细胞中的EC50约为3 nM。
靶点
Smoothened [1]
(mouse cultured cell assay)
3 nM(EC50)
体外研究

SAG通过直接结合到Smo螺旋束调控Smo活性。[1] SAG以GRK2依赖的方式诱导通过Gli的Smo-依赖性信号。[2] SAG(1 nM)也会诱导神经元和神经胶质前体细胞的增殖,而不影响新生细胞的分化模式。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse Shh-Light II cell M3vYTWZ2dmO2aX;uJIF{e2G7 NWH4NW9PPDhiaILz NYnZXHdpSWO2aY\heIlwdiCxZjDTbIgheGG2aIfhfUBqdiCvb4Xz[UBUcGhvTHnnbJQhUUliY3XscJMh[XO|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJIdtcTFiZYjwdoV{e2mxbjDh[pRmeiB2ODDodpMh[nlicnXubYxt[SCudX3pcoV{[2WwY3WgZZN{[XluIFXDOVA:OC5yMEi4JO69VQ>? MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl6NUm1PEc,OjJ7OEW5OVg9N2F-
HUVEC NUWyNWF4S3m2b4TvfIlkcXS7IHHzd4F6 M1XFVlI1KGh? MlWyR5l1d3SxeHnjbZR6KGGpYXnud5QhUFWYRVOgZYZ1\XJiMkSgbJJ{KGK7IGfTWE0yKGG|c3H5MEBKSzVyPUKyJO69VQ>? Mnr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7OEW5OVgoRjJ{OUi1PVU5RC:jPh?=
Shh-Light II NEPPN|hHfW6ldHnvckBie3OjeR?= NFHrXGM1QCCqcoO= MULBZ5RqfmG2aX;uJI9nKFOqaDDwZZRpf2G7IHnuJI1wfXOnIGPobE1NcWeqdDDJTUBk\WyuczDhd5Nme3OnZDDhd{BqdmS3Y4Tpc44hd2ZiZ3zpNUBmgHC{ZYPzbY9vKGGodHXyJFQ5KGi{czDifUBz\W6rbHzhJIx2dWmwZYPj[Y5k\SCjc4PhfUwhTUN3MDC9JFAvODZzODFOwG0v MlfDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7OEW5OVgoRjJ{OUi1PVU5RC:jPh?=
NIH/3T3 NETPR3hHfW6ldHnvckBie3OjeR?= NY[wOFZrSWexbnnzeEBi[3Srdnn0fUBifCCVbX:gbY4hdW:3c3WgUmlJNzOWMzDj[YxteyC2cnHud4Zm[3SnZDD3bZRpKEeuaT3k[ZBmdmSnboSg[olz\W[ueTDseYNq\mW{YYPlJJJmeG:{dHXyJIF{e2W|c3XkJIF{KHO2aX31cIF1cW:wIH;mJGdtcSC2cnHud4NzcXC2aX;uJIZi[3SxcjygSWM2OCB;IECuNFMh|ryPLh?= NUnTSJB6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke0NlkzPTVpPkK3OFI6OjV3PD;hQi=>
C3H10T1/2 NFnMbJlHfW6ldHnvckBie3OjeR?= M4PUXlYh\GG7cx?= M2OwWGFod26rc4SgZYN1cX[rdImgZZQhW22xIHnuJI1wfXOnIFOzTFExXDFxMjDj[YxteyCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4Yh[2WubDDkbYZn\XKnboTpZZRqd25iaX70c{Bwe3Snb3LsZZN1KGmwY4XiZZRm\CCob4KgOkBl[Xm|IHL5JIFtc2GuaX7lJJBpd3OyaHH0ZZNmKGG|c3H5MEBGSzVyIE2gNE4yOyEQvF2u M1nqZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5NEK5NlU2Lz5{N{SyPVI2PTxxYU6=
A673 MV;xTHRUKGG|c3H5 NGrPV5hyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= NEiwcIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 NYfsc2l{eUiWUzDhd5NigQ>? MmHXdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOjb4OtNkBk\Wyucx?= M1zOeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37 NFSzUXJyUFSVIHHzd4F6 NFnBcXpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= M3PJOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD NULlXpVDeUiWUzDhd5NigQ>? MmqxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKGIHPlcIx{ NXHY[YF2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH MWjxTHRUKGG|c3H5 MnHzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO= M{e2fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-12 MoOydWhVWyCjc4PhfS=> NFrIR4lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO= MlzPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R) M332dZFJXFNiYYPzZZk> NF;xUYxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO= MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
NB1643 NUHUUXc6eUiWUzDhd5NigQ>? Mn;adWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= NELuXFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 M{SzXpFJXFNiYYPzZZk> M{TW[JFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO= NXnq[3ZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2 NVfhcIVKeUiWUzDhd5NigQ>? Ml7ndWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-MC NY[wSmZNeUiWUzDhd5NigQ>? M1;KXJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz NX7mSlZ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 M3PQV5FJXFNiYYPzZZk> NHmwTllyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh18 NIjjXVJyUFSVIHHzd4F6 MlTNdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
LC3I / LC3II; 

PubMed: 23504944     


Western blotting for LC3I/II. Huh7, Hep3B and HepG2 cells were incubated with vehicle control, SAG (0.5 µM), Pur (10 µM), Shh (0.4 µg/ml), GANT61 (20 µM) or GDC0449 (20 µM) for 48 hours.

23504944
Immunofluorescence
Smo; 

PubMed: 25636740     


In the absence of SAG, Smo is not detected at the cilium. MRT-92 alone does not induce Smo trafficking to the primary cilium. Cell exposure to SAG induces Smo trafficking to the cilium, which is abolished by MRT-92.

acetylated alpha tubulin; 

PubMed: 25992706     


TM3 cells were cultured in the presence of the SMO agonist (SAG) to monitor response to HH activation. A) In control cells (a-c; 0 h), primary cilia marked by Ac-T (red; arrows) only displayed occasional, speckled appearance of SMO (green). After 1 h in the presence of 100 nM SAG (d-f), a stronger and more frequent localization of SMO to the primary cilia was observed, now also at the ciliary base (f; insert; arrow), and this was even more apparent after 4 h of SAG-stimulation (g-i). Nuceli were stained with DAPI. Scale bar = 10 μm. 

25636740 25992706
体内研究 在成年大鼠海马中,SAG (2.5 nM)脑室内给药显著增加新生细胞的数量,并延长海马细胞的存活时间。[3]在小鼠中,SAG (20 μg/g, i.p.)有效防止GC-诱导的新生小脑发育异常。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

动物实验:[3]
- 合并
  • Animal Models: 大鼠
  • Dosages: 2.5 nM
  • Administration: 侧脑室给药
    (Only for Reference)

溶解度 (25°C)

体外 Water 100 mg/mL (189.92 mM)
DMSO 71 mg/mL warmed (134.84 mM)
Ethanol 40 mg/mL warmed (75.97 mM)
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
water
100mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 526.52
化学式

C28H29Cl2N3OS

CAS号 2095432-58-7
储存条件 粉状
溶于溶剂
别名 N/A

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT02044068 Completed -- Vertical Disease Transmission|HBV Hopital Lariboisière October 2014 --
NCT02058134 Terminated Device: cardioPAT cell saver Coronary Artery Disease|Aortic Stenosis|Aortic Insufficiency|Mitral Insufficiency|Aortic Aneurysm Rigshospitalet Denmark December 2013 Not Applicable
NCT01264094 Terminated Drug: Clevudine Chronic Hepatitis B Bukwang Pharmaceutical November 2009 Phase 4

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

Hedgehog/Smoothened Signaling Pathway Map

相关Hedgehog/Smoothened产品

Tags: 购买Smoothened Agonist (SAG) HCl | Smoothened Agonist (SAG) HCl供应商 | 采购Smoothened Agonist (SAG) HCl | Smoothened Agonist (SAG) HCl价格 | Smoothened Agonist (SAG) HCl生产 | 订购Smoothened Agonist (SAG) HCl | Smoothened Agonist (SAG) HCl代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID